 Biocept Inc NASDAQ: BIOC received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells CTCs. Reimbursement decision expands access to testing used to provide information to guide targeted treatment options for patients with breast cancer. 